Jakubowitz Law
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Ardelyx Inc. (ARDX)

the likelihood that tenapanor would be approved by the Food and Drug Administration (“FDA”). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug’s treatment effect, making it foreseeably likely that the FDA would not approve the drug.

If you incurred a loss on ARDX stocks purchased between August 6, 2020 and July 19, 2021, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Northern District of California, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until September 28, 2021 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Enter the following information for this class action case- the deadline is approaching.

See If you Qualify for Monetary Reward

Loss Submission Form

Submitting your information does not create an attorney-client relationship and you are giving us your express consent to contact you by email, text message, SMS, or call you by telephone.